Breast Cancer
A page on conditions in our medical research coverage, part of our health reporting, alongside the 34 reports filed on it so far.
Combination therapy achieves high major pathological response in pMMR colon cancer
The UNICORN phase 2 trial shows neoadjuvant botensilimab plus balstilimab produced a 36% major pathological response in pMMR colon cancer and 100% in...
Early-Onset Colorectal Cancer Tumors Show Distinct Cellular Composition
A new single-nucleus RNA sequencing atlas reveals that colorectal cancers in younger patients have a higher proportion of stromal cells and lower...
PET-Guided Strategy Enables Chemotherapy De-Escalation in HER2-Positive Breast Cancer
Long-term data from the phase II PHERGain trial shows a PET-guided, response-adapted strategy allowed many patients with HER2-positive early breast...
BioNTech's trastuzumab pamirtecan shows modest PFS benefit in HER2-low breast cancer
A Phase 3 trial for BioNTech and DualityBio's antibody-drug conjugate trastuzumab pamirtecan met its primary endpoint, delaying tumor progression in...
Camupepimut vaccine shows benefit in pancreatic cancer subgroup
The AMPLIFY-7P phase 2 trial found camupepimut did not improve disease-free survival overall but showed significant benefit in ctDNA-negative...
FDA expands Anktiva approval for BCG-unresponsive bladder cancer
The FDA has expanded approval of nogapendekin alfa inbakicept-pmln (Anktiva) with BCG to treat adults with BCG-unresponsive, high-grade...
Helen Branswell, STAT medical journalist, dies at 69
Helen Branswell, a pioneering medical journalist and co-founder of STAT, has died at age 69. Her death on Tuesday in an Ottawa hospital followed...
BioNTech's BNT113 Fails Key Goal in Head and Neck Cancer Trial
BioNTech's mRNA cancer therapy BNT113 combined with Keytruda did not improve progression-free survival in a Phase 3 trial for HPV-driven head and...
Caribou Biosciences discontinues CAR-T therapies, cuts staff
Caribou Biosciences is halting development of two off-the-shelf CAR-T cancer therapies, including its Phase 3-ready candidate vispa-cel, and laying...
ArriVent's furmonertinib fails key lung cancer trial endpoint
ArriVent BioPharma's oral lung cancer drug furmonertinib failed to significantly delay tumor progression versus chemotherapy in a late-stage study...
FDA Staff See No Major Safety Issues With Grail's Galleri
FDA reviewers identified no major safety or accuracy concerns with Grail's Galleri multi-cancer early detection blood test.
EVOKE-03 Trial: Sacituzumab Fails to Boost Survival
The phase III EVOKE-03 trial found adding sacituzumab govitecan to pembrolizumab did not significantly improve survival in untreated metastatic...
Cullinan and Taiho drug extends lung cancer progression-free survival
In a phase 3 trial, adding zipalertinib to chemotherapy improved median progression-free survival to 14.5 months, a six-month gain over chemo alone.
GSK's risvutatug rezetecan shows 18.5-month median overall survival
GSK and Hansoh Pharma's antibody-drug conjugate risvutatug rezetecan achieved a median overall survival of 18.5 months in a phase 3 trial for...
FDA delays Exelixis' zanzalintinib decision to March 2027
The FDA has postponed its approval decision for Exelixis' oral kinase inhibitor zanzalintinib in metastatic colorectal cancer, requesting updated...
FDA approves AstraZeneca's Etcamah for ctDNA-guided breast cancer treatment
The FDA granted accelerated approval to AstraZeneca's camizestrant (Etcamah) for HR-positive, HER2-negative breast cancer patients with an ESR1...
Akeso's Ivonescimab Shows Lung Cancer Survival Edge
Akeso and Summit Therapeutics report their bispecific antibody ivonescimab helped lung cancer patients live longer than those on Merck's Keytruda.
Induced Proximity Therapies Gain Ground After First PROTAC Approval
The first FDA-approved PROTAC drug for breast cancer has validated a new class of medicines that work by bringing proteins together.
FDA Grants Accelerated Approval to AstraZeneca's Etcamah
The FDA has granted accelerated approval to AstraZeneca's Etcamah for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.
Natera partners with Angiex on cancer trial
Natera has partnered with Angiex to evaluate its Signatera blood test in a phase 1 trial of the cancer drug AGX101.
mRNA cancer vaccine trial succeeds
A personalized mRNA vaccine for melanoma from Moderna and Merck has shown clinical success.
BioNTech-Genentech cancer vaccine trial ends after deaths
BioNTech and Genentech ended a trial of their mRNA cancer vaccine after more deaths occurred in the vaccinated group versus the observation group.
FDA clears three updated COVID-19 vaccines
The FDA approved updated COVID-19 vaccines from Pfizer, Moderna, and Novavax. Moderna also raised $2.6 billion for its cancer drug business.
AstraZeneca halts cancer drug trial in setback
AstraZeneca halts cancer drug trial in setback. A target trial emulation of adults with serious mental illness (SMI) found GLP-1 receptor agonists...